- Report
- July 2023
- 253 Pages
Global
From €3175EUR$3,600USD£2,790GBP
- Report
- February 2024
- 150 Pages
Global
From €4190EUR$4,750USD£3,681GBP
- Report
- March 2023
- 158 Pages
Africa, Middle East
From €3396EUR$3,850USD£2,983GBP
€4278EUR$4,850USD£3,758GBP
- Report
- June 2025
- 250 Pages
India
From €2460EUR$2,789USD£2,161GBP
- Report
- October 2025
- 100 Pages
Qatar
From €4278EUR$4,850USD£3,758GBP
- Report
- January 2022
- 243 Pages
Europe
From €4896EUR$5,550USD£4,301GBP
- Report
- March 2024
- 80 Pages
Global
From €3500EUR$4,251USD£3,182GBP
- Report
- January 2024
- 116 Pages
Global
From €3500EUR$4,251USD£3,182GBP
- Report
- February 2024
- 132 Pages
Global
From €838EUR$950USD£736GBP
The High Potency API (HPAI) market is a subset of the pharmaceutical intermediates market, focusing on the production of active pharmaceutical ingredients (APIs) with high potency. These APIs are used in the manufacture of drugs and other pharmaceutical products, and are typically produced in small quantities due to their potency. HPAI production requires specialized equipment and processes, as well as stringent safety protocols, to ensure the safety of workers and the environment.
HPAI production is a complex process, involving multiple steps such as synthesis, purification, and formulation. The production of HPAI is highly regulated, and manufacturers must adhere to strict quality standards to ensure the safety and efficacy of their products.
Companies in the HPAI market include Lonza, Boehringer Ingelheim, Dr. Reddy's Laboratories, and Aurobindo Pharma. Show Less Read more
